P103 Natural compounds in Ulcerative Colitis and Irritable Bowel Syndrome: Insights from immune-metabolic profiles

C McShane,F O'Connell,M Pigott,I Obaidi,H Sheridan,D Kevans,J O'Sullivan

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0233

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) represent chronic and occasionally disabling conditions, necessitating innovative treatment strategies. Covering 14% of Ireland's landscape, bogland ecosystems house unique plant biodiversity, yielding biologically active secondary metabolites. Informed by traditional medicinal knowledge and in vitro screening for immunomodulatory potential, three plant extracts (NTP0226A, NTP0127B, NTP0206EA) were selected for exploration of their potential to treat IBD and IBS within the "Unlocking Nature’s Pharmacy from Bogland Species" project. Methods Patients undergoing colonoscopy were prospectively recruited in three cohorts: healthy controls, IBS, and ulcerative colitis (UC). Recto-sigmoid biopsies were collected and cultured for 24 h with treatments (Infliximab, NTP0226A, NTP0127B, NTP0206EA). Colonic tissue explants underwent real-time energy metabolism profiling and quantification of 10 inflammatory mediators using Seahorse Xfe24 analyser and multiplex ELISA, respectively. P values <0.05 were considered significant in analyses. Results Twenty-seven patients were recruited (6 healthy controls, 6 IBS, and 15 UC). UC patient explants exhibited elevated glycolytic metabolism and increased IL-4, IL-6, and IL-12p70 secretion compared to non-UC patients. No differences were observed between healthy controls and IBS patients. Linear regression did not show correlation between age and mitochondrial bioenergetics. There was no change in metabolism profiles of any cohort following treatment with Infliximab or the 3 novel extracts. In the UC tissue, treatment with Infliximab reduced IL-12p70 secretion (p=0.0098), this reduction was not seen in the other 2 cohorts. NTP0206EA reduced IL-10 secretion in the UC cohort (p=0.0255). In the IBS cohort; NTP0127B reduced IL-10 secretion (p=0.0048) and NTP0226A reduced IL-4 (p=0.004) and IL-6 (p=0.0219) secretion. Principal component analysis demonstrated reduced separation between the immune-metabolic profiles of UC patients and healthy controls following treatment with NTP0226A (Figure 1). Conclusion Using an explant model, we have shown that UC patients have a distinct immune-metabolic profile modifiable by a standard IBD therapy and novel plant extracts. Blockade of IL-6 trans-signalling has recently shown promise as an effective treatment target in IBD. Our natural extract NTP0226A reduced IL-6 secretion in IBS patients and is a promising candidate for therapeutic exploration. These findings contribute to our understanding of the complex interplay in the colonic microenvironment and highlight potential avenues for novel therapeutic interventions.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem this paper attempts to address is the exploration of the potential therapeutic effects of natural compounds from the Irish bog ecosystem on inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Specifically, researchers selected three plant extracts (NTP0226A, NTP0127B, NTP0206EA) from traditional medicinal knowledge and in vitro screening, and experimentally validated the role of these extracts in regulating immunometabolism, with the aim of discovering new therapeutic strategies.

### Background
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are chronic and sometimes debilitating conditions that require innovative treatment approaches. The Irish bog ecosystem covers 14% of the country's land area and has a unique plant diversity capable of producing bioactive secondary metabolites. Based on traditional medicinal knowledge and the immunomodulatory potential from in vitro screening, researchers selected three plant extracts (NTP0226A, NTP0127B, NTP0206EA) for further study.

### Methods
The study recruited three groups of patients: healthy controls, IBS patients, and ulcerative colitis (UC) patients. Rectosigmoid biopsy tissues were collected via colonoscopy and cultured with different treatments (including infliximab, NTP0226A, NTP0127B, NTP0206EA) within 24 hours. Real-time energy metabolism analysis was performed using the Seahorse Xfe24 analyzer, and the levels of 10 inflammatory mediators were measured by multiplex ELISA. A p-value of less than 0.05 was considered statistically significant.

### Results
A total of 27 patients were recruited (6 healthy controls, 6 IBS patients, 15 UC patients). Biopsies from UC patients showed enhanced glycolytic metabolism and increased secretion of IL-4, IL-6, and IL-12p70, while no significant differences were observed between healthy controls and IBS patients. Linear regression analysis did not show a correlation between age and mitochondrial bioenergetics. Treatment with infliximab or the three novel extracts did not alter the metabolic profiles in any group. Infliximab reduced IL-12p70 secretion in UC tissues (p=0.0098), but this reduction was not observed in the other two groups. NTP0206EA reduced IL-10 secretion in the UC group (p=0.0255). In the IBS group, NTP0127B reduced IL-10 secretion (p=0.0048), and NTP0226A reduced IL-4 (p=0.004) and IL-6 (p=0.0219) secretion. Principal component analysis showed reduced separation of immunometabolic profiles between UC patients and healthy controls after NTP0226A treatment.

### Conclusion
Through the tissue biopsy model, the study found that UC patients have a unique immunometabolic profile that can be modulated by standard IBD therapies and novel plant extracts. Blocking IL-6 trans-signaling has recently shown potential as an effective therapeutic target for IBD. The natural extract NTP0226A reduced IL-6 secretion in IBS patients, making it a potential therapeutic candidate. These findings contribute to understanding the complex interactions within the colonic microenvironment and provide potential directions for novel therapeutic interventions.